Targeting Respiratory Disease: Clinical Progress of ETH47, a Nasally Administered mRNA Therapeutic for Asthma
11:30 am - Thursday 18th February 2027
- Exploring localised respiratory delivery of therapeutic mRNA to achieve dose-dependent protein expression while minimising systemic exposure
- Evaluating the safety, tolerability and biodistribution of nasal and inhaled mRNA formulations to support therapeutic development in respiratory diseases
- Sharing Phase IIa clinical proof-of-concept findings from a rhinovirus challenge study in asthma patients, assessing therapeutic activity and symptom reduction
